UNITED STATES PATENT AND TRADEMARK OFFIC	Έ
BEFORE THE PATENT TRIAL AND APPEAL BOARD)
MYLAN PHARMACEUTICALS INC. Petitioner,	
v.	
ICOS CORP.	
Patent Owner.	
Patent No. 6,943,166	

DECLARATION OF GEORGE GRASS, PHARM.D., PH.D.

TABLE OF CONTENTS

I.	Qualifications	1
II.	Scope of Work	2
III.	Overview of the '166 Patent	2
IV.	Brief Summary of the File History of the '166 Patent	5
V.	Legal Standards	.15
VI.	Level of Ordinary Skill and Relevant Time	.18
VII.	Claim Construction	20
VIII.	The State of the Art	22
IX.	The Asserted References Disclose or Suggest Each of the Claimed	
	Features of the '166 Patent	29
X.	The Claimed Dosing Method Does Not Produce Unexpected Results	.49
XI.	Concluding Statements	.64
XIII.	Appendix – List Of Exhibits	66



I, George Grass, declare as follows:

I. QUALIFICATIONS

- 1. My name is George M. Grass IV. I have been working in the drug discovery and biotechnology industries since 1985. I am currently President of a consulting business, G2 Research Inc., and Sr. Vice President of Non-Clinical Development for NeuroVia Inc.
- I received a Pharm. D. from the University of Nebraska in 1980, a
 M.S. in Pharmaceutics from the University of Wisconsin in 1983, and a Ph.D. in
 Pharmaceutics from the University of Wisconsin in 1985.
- 3. My primary areas of technical expertise are drug development, drug delivery, and pharmacokinetics, including computational simulations and modeling of pharmacokinetic processes.
- 4. In previous professional roles, I have served as a researcher, an executive, or a consultant for numerous drug development and biotechnology companies, including Sorbent Therapeutics, PDxRx Inc., Trega Biosciences, NaviCyte, Inc., Precision Instrument Design, Inc., and Syntex Research.
- 5. I have authored over 30 publications related to drug development, drug delivery and pharmacokinetics, including book chapters and peer-reviewed journal articles. I have authored over 30 abstracts for presentation at professional



meetings. I am also an inventor or co-inventor on 12 patent applications, including eight awarded patents.

6. A summary of my experience, education, publications and other qualifications is provided in my CV, a copy of which is submitted separately. EX1003.

II. SCOPE OF WORK

- 7. I understand that a petition is being filed with the United States Patent and Trademark Office for *Inter Partes Review* of U.S. Patent No. 6,943,166 ("the '166 patent," EX1001). I have been retained by Mylan Pharmaceuticals Inc. as a technical expert to provide analysis and opinions regarding the '166 patent. I have reviewed the '166 patent and sections of its prosecution history in the United States Patent and Trademark Office. EX1006. I have also reviewed and considered various other documents in arriving at my opinions, and I cite them in this declaration. For convenience, documents cited in this declaration are listed in the Appendix in Section XIII.
- 8. I am compensated at the rate of \$575/hour for my work. I have no financial interest in the outcome of this matter.

III. OVERVIEW OF THE '166 PATENT

9. The '166 patent issued on September 13, 2005. The '166 patent is titled "Compositions Comprising Phosphodiesterase Inhibitors for the Treatment of



Sexual Dysfunction." The first page of the patent states that an application for the '166 patent (U.S. Application No. 10/031,556), was filed as a national stage entry application of PCT/US00/11129 and claims priority to provisional U.S. Application No. 60/132,036, filed on April 30, 1999.

10. The '166 patent is generally directed to the treatment of sexual dysfunction, including male erectile dysfunction and female arousal disorder using the compound (6*R*,12a*R*)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, referred to herein for convenience as "tadalafil," and also referred to in the '166 patent as Compound I. EX1001, 2:58-63. Tadalafil is marketed under the trademark Cialis[®]. Cialis[®] Approved Label ("Cialis[®] Label," EX1010). The '166 patent states:

The biochemical, physiological, and clinical effects of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase (cGMP-specific PDE) inhibitors suggest their utility in a variety of disease states in which modulation of smooth muscle, renal, hemostatic, inflammatory, and/or endocrine function is desired. Type 5 cGMP-specific phosphodiesterase (PDE5) is the major cGMP hydrolyzing enzyme in vascular smooth muscle, and its expression in penile corpus cavernosum has been reported. Thus, PDE5 is an attractive target in the treatment of sexual dysfunction. *Id.* at 1:29-40 (citations omitted).



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

